-
Mashup Score: 0Don't Miss a Beat: oHCM and Mavacamten - 2 year(s) ago
Listen to this episode from Don’t Miss a Beat on Spotify. A first-in-class allosteric and reversible inhibitor selective for cardiac myosin approved based on the results of the EXPLORER-HCM trial, mavacamten was approved for the treatment of adults with symptomatic NYHA class 2-3 obstructive hypertrophic cardiomyopathy after their phase 3 data indicated use was with improved exercise capacity,…
Source: SpotifyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT - 3 year(s) ago
Since women tend to bleed more post-PCI, there may be greater incentive to dropping aspiring earlier, one investigator says.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
3. Dont forget to get the news from #ACC21 & expert insight from @TCTMD with #TWILIGHT https://t.co/EPMYjEe1ov AND #EXPLORER_HCM https://t.co/aA90CiTdA4 @Drroxmehran @DrLaxmiMehta @cardioPCImom @ajaykirtane @ovidiogarciav @omendiz @sbrugaletta @Ortega_Paz @safinmc @ShelleyWood2 https://t.co/aD4L6Nel7l
-
-
Mashup Score: 0Study Design and Rationale of EXPLORER-HCM - 3 year(s) ago
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical ther
Source: Circulation: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
⬆️ #EXPLORER_HCM @TheLancet Here the study design & rationale @CircHF @EClinicalMed @SABOURETCardio @mirvatalasnag @ShelleyZieroth @MicheleSenni @HFA_President @HFSAa @mmamas1973 @DrRajivsankar @lucreciamburgos @azangrillo @DrDEliaEmilia @Dr_Manito https://t.co/iXAs4QAgji https://t.co/y9EkiJcC6u
-
-
Mashup Score: 4
Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. The results of this pivotal trial highlight the benefits of disease-specific treatment for this condition.
Source: The LancetCategories: Cardiologists, Latest HeadlinesTweet-
Remembering the important results of #EXPLORER_HCM. #Mavacamtem is one of the most important novelties in the #Cardiomyopathies world over the last 10 years. A new hope for #HOCM @IacopoOlivotto @MarcoMetra @rahatheart1 @iamritu @DrMarthaGulati @zhh_ch https://t.co/AgSh6Tk3c9 https://t.co/zKg8LDMzZH
-
This month on #DontMissABeat, @mvaduganathan & I were honored to discuss #EXPLORER_HCM & #mavacamten w/ guest #HCM expert @tikuowens! ✅trial design &🔑results ✅#RCT endpoint considerations for #HCM ✅magnitude of KCCQ benefit ✅implementation https://t.co/PuT52ErjAq https://t.co/V1tGs4I8lP